Inventor · disambiguated record
John K. Sullivan
Also filed as: SULLIVAN JOHN K · SULLIVAN JOHN KEVIN
13 granted patents·10 pending applications·284 citations·filing 1998–2013
93Inventor score
Top patents by PatentIndex Score
23 records- 0196US7803769B2OSK1 peptide analogs and pharmaceutical compositionsAMGEN INC·Filed 2007·Granted Sep 28, 2010·46 cites·3 claims
- 0295US7833979B2Toxin peptide therapeutic agentsAMGEN INC·Filed 2006·Granted Nov 16, 2010·45 cites·31 claims
- 0394US8907071B2Toxin peptide therapeutic agentsSULLIVAN JOHN K·Filed 2010·Granted Dec 9, 2014·61 cites·24 claims
- 0490US7414122B2Nucleic acids encoding B7-Like molecules and uses thereofAMGEN INC·Filed 2004·Granted Aug 19, 2008·48 cites·12 claims
- 0589US7834164B2DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expressionAMGEN INC·Filed 2007·Granted Nov 16, 2010·9 cites·8 claims
- 0689US7820623B2Conjugated toxin peptide therapeutic agentsAMGEN INC·Filed 2007·Granted Oct 26, 2010·10 cites·23 claims
- 0785US8043829B2DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expressionAMGEN INC·Filed 2007·Granted Oct 25, 2011·6 cites·19 claims
- 0884US6344541B1DKR polypeptidesAMGEN INC·Filed 1998·Granted Feb 5, 2002·49 cites·3 claims
- 0983US7825093B2Methods of using OSK1 peptide analogsAMGEN INC·Filed 2007·Granted Nov 2, 2010·4 cites·3 claims
- 1082US7910102B2Methods of using conjugated toxin peptide therapeutic agentsAMGEN INC·Filed 2007·Granted Mar 22, 2011·4 cites·12 claims
- 1177US7723478B2DKR polypeptidesAMGEN INC·Filed 2007·Granted May 25, 2010·2 cites·3 claims
- 1265US2005153330A1Novel DKR polypeptidesAMGEN INC·Filed 2004·Application pending·0 cites
- 1360US2013171168A1Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway InhibitorsAMGEN INC·Filed 2013·Application pending·0 cites
- 1460US2013164292A1Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway InhibitorsAMGEN INC·Filed 2012·Application pending·0 cites
- 1559US8455629B2Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitorsBOYLE WILLIAM J·Filed 2012·Granted Jun 4, 2013·0 cites·18 claims
- 1659US2009004237A1B7-Like Molecules and Uses ThereofAMGEN INC·Filed 2008·Application pending·0 cites
- 1756US8367063B2Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitorsAMGEN INC·Filed 2010·Granted Feb 5, 2013·0 cites·32 claims
- 1856US2002161178A1Novel DKR polypeptidesAMGEN INC·Filed 2001·Application pending·0 cites
- 1953US2010209435A1Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway InhibitorsAMGEN INC·Filed 2010·Application pending·0 cites
- 2050US2014147444A1Selective binding agents of osteoprotegerin binding proteinAMGEN INC·Filed 2013·Application pending·0 cites
- 2146US2002107363A1B7-Like molecules and uses thereofAMGEN INC·Filed 2001·Application pending·0 cites
- 2245US2003103978A1Selective binding agents of osteoprotegerin binding proteinAMGEN INC·Filed 2001·Application pending·0 cites
- 2335US2002165347A1B7-like molecules and uses thereofAMGEN INC·Filed 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John K. Sullivan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →